Mullane, Stephanie A.
Werner, Lillian
Rosenberg, Jonathan
Signoretti, Sabina
Callea, Marcella
Choueiri, Toni K.
Freeman, Gordon J.
Bellmunt, Joaquim
Article History
Received: 2 February 2016
Accepted: 18 May 2016
First Online: 10 June 2016
Competing interests
: Joaquim Bellmunt: Consultant for Pierre Fabre, Astellas, Pfizer; Merck; Genentech. Gordon Freedman: Research funding from Takeda, Sanofi Gordon Freedman: Pending patent royalties on PD-1 pathway from BMS, Roche, Merck, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Novartis. Advisory Borad: CoStim, Novartis, Roche, BMS. Toni K. Choueiri: Consulting or Advisory for: Pfizer, GSK, Novartis, Merck, Bayer. Research funding: BMS, Merck, Exelixis, Roche, AstraZeneca, Tracon. Other coauthors: none.